Ascentage. With respect to each Compound designated as a Development Compound, Ascentage shall meet the diligence requirements set forth in Exhibit 3.4.2. In the event that Ascentage fails to meet such diligence requirements and fails to cure such default accordance with Section 12.2, Ascentage’s right to continue to develop such Development Candidate will terminate, Ascentage shall [***] discontinue ([***]) all development activities with respect to such Development Candidate.
Appears in 4 contracts
Samples: Compound License Agreement (Unity Biotechnology, Inc.), Restricted Stock Grant Agreement (Unity Biotechnology, Inc.), Compound License Agreement (Unity Biotechnology, Inc.)
